---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-038299"
form_type: "8-K"
ticker: "REGN"
cik: "0000872589"
company_name: "REGENERON PHARMACEUTICALS, INC."
filed_at: "2023-03-29T23:59:59+00:00"
generated_at: "2026-06-17T11:34:00.443093+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Regeneron amends $720M lease financing to align covenants with Dec 2022 credit agreement

## Summary
- Third A&R Participation Agreement aligns financial and operating covenants with credit agreement entered December 2022.
- $720 million lease financing for corporate headquarters; maturity remains March 2027 with 5-year extension option.
- Yield on advances unchanged, based on 1-month SOFR term rate plus spread and margin tied to debt rating/leverage.
- No new borrowing; amendment and restatement of existing facility; lease term extended previously to 2027.
- Regeneron guarantees obligations; subsidiary guarantors only join if they have borrowings under the credit agreement.

## SEC filing metadata
- accession: 0001104659-23-038299
- form_type: 8-K
- ticker: REGN
- cik: 0000872589
- company_name: REGENERON PHARMACEUTICALS, INC.
- filed_at: 2023-03-29T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.03, 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/872589/000110465923038299/0001104659-23-038299-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/872589/000110465923038299/tm2310647d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-038299
- JSON: https://secwatch.observer/filing/0001104659-23-038299.json
- Plain text: https://secwatch.observer/filing/0001104659-23-038299.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.